SCD-HeFT
2005
Sudden Cardiac Death in Heart Failure Trial
In 2,521 patients with heart failure (NYHA II–III, EF ≤ 35 %), an implantable defibrillator reduced all-cause mortality compared with placebo or amiodarone.
Result
Primary endpoint: All-cause mortality
ICD HR 0.77; amiodarone no better than placebo.
- Subtopic
- ICD
- Design
- RCT, double-blind drug arms
- Relevance
- Practice-defining: a trial the guidelines cite as evidence.
- Source
- Bardy GH, et al. N Engl J Med. 2005;352(3):225-237.doi 10.1056/NEJMoa043399
Discussion & critique
Extended ICD benefit to non-ischaemic HF and showed amiodarone is not prognostically useful. The benefit was concentrated in NYHA class II.